Nutritional and Metabolic Diseases
Conditions
Keywords
urate oxidase, hyperuricemia, lymphoma, leukemia
Brief summary
Primary: To estimate efficacy of SR29142 to the pediatric patients with newly diagnosed hematological malignancies at high risk for Tumor Lysis Syndrome, by evaluation of plasma uric acid concentration. Secondary: To investigate the safety in this population and anti-SR29142 antibodies, anti-SCP antibodies, and pharmacokinetic parameters.
Interventions
Sponsors
Sanofi
Study design
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
* \<18 years of age * Patient with newly diagnosed hematological malignancies presenting with hyperuricemia: * Uric acid \> 7.5 mg/dL in patients ≥ 13 years old- Uric acid \> 6.5mg/dL in patients \<13 years old Or, patient with newly diagnosed hematological malignancies presenting with high tumor burden defined: * Non-Hodgkin's lymphoma, Stage IV regardless of uric acid level, * Non-Hodgkin's Lymphomas stage III regardless of uric acid level with one of the following: * At least one lymph node or mass \>5 cm in diameter * LDH ≥ 3 x ULN (IU/L): Judging according to modified Murphy's classification * Acute leukemia with white blood cell count (WBC) ≥ 50,000/mm3 or LDH ≥ 3 x ULN (IU/L) regardless of uric acid level. etc.
Exclusion criteria
* Patients who have received or are scheduled to receive other investigational drugs in 30 days prior to the start of SR29142 administration or during the trial period. * Low birth weight infant (\<2500g) or gestational age \<37 weeks * Patients who have received or are scheduled allopurinol within 72 hrs prior to the first dose of SR29142 or during the trial period. * Known history of severe allergic reaction and/or severe asthma. * Known history or family history of glucose-6-phosphate dehydrogenase deficiency. * Known history of hemolysis and methemoglobinemia. * Severe disorders of liver or kidney. ALT (GPT) \> 5.0 x ULN, Total Bilirubin \> 3.0 x ULN, Creatinine \> 3.0 x ULN * Uncontrollable infections (including viral infections). * Known positive tests for HBs antigen, HCV antibodies, or HIV-1, 2 antibodies. etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients with a plasma uric acid level decreased to the endpoint by 48 hr after the start of first drug infusion and lasting until 24 hr after the start of final (Day 5) drug infusion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety will be assessed on clinical observation, laboratory test, vital sign (blood pressure, pulse rate and body temperature), and the occurrence of adverse events. | — |
| G6PD activity will be measured in only patients who demonstrate hemolysis. | — |
| Anti-SR29142 antibody and Anti-SCP antibody will be measured. | — |
| PK parameters. | — |
Countries
Japan
Outcome results
None listed